KRAS and familial pancreatic carcinoma: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations are critical drivers of tumor progression and metastasis, frequently occurring in colorectal cancer, pancreatic cancer, and lung cancer.[23] Among the various KRAS mutations, those occurring at codons 12, specifically G12D, G12V and G12C, are the most prevalent across all tumor types.[24] Consequently, KRAS‐G12 mutations are considered promising targets for tumor therapy.